EVOLUTION HF UK
Research type
Research Study
Full title
Early treatment of heart failure: a non-interventional observational study program of patients with heart failure and initiated on dapagliflozin (EVOLUTION-HF UK)
IRAS ID
296166
Contact name
Steven Coombs
Contact email
Sponsor organisation
AstraZeneca
Duration of Study in the UK
1 years, 8 months, 31 days
Research summary
The overall aim of this study is to describe the characteristics of patients started on dapagliflozin for the treatment of heart failure (HF) and to provide information on treatment patterns, as well as patient-reported outcomes (PROs) including quality of life. \n\nThis research is important because HF is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients’ health-related quality of life (HRQoL).\n\nClinical information will be collected from the health records of patients enrolled. Additional data such as PROs will be collected directly from patients. Data collection will involve assessments at enrolment into the study, and separate follow-up assessments at 3, 6, 9 and 12 months following enrolment.\n\nThe research will take place at about 10 hospitals across the UK and is sponsored by AstraZeneca UK.
REC name
North of Scotland Research Ethics Committee 2
REC reference
21/NS/0102
Date of REC Opinion
4 Aug 2021
REC opinion
Favourable Opinion